The present invention relates to new pyrazole derivatives possessing an amide group substituted with an amino acid or one of its derivatives at position 3 and variously substituted in positions 1, 2, 4 or 5 of the pyrazole ring, to a process for preparing these and to pharmaceutical compositions containing the said pyrazole derivatives as an active ingredient.
This application is a Divisional of application Ser. No. 08/394,756, filed Feb. 27, 1995, U.S. Pat. No. 5,616,592, which is a Divisional of application Ser. No. 08/119,830, filed Sep. 13, 1993 (now U.S. Pat. No. 5,420,141), which is a Continuation of application Ser. No. 07/747,359, filed Aug. 20, 1991 (now abandoned).
The present application describes compounds according to Formula I, wherein A, B, E, R.sup.1, R.sup.2, R.sup.3, R.sup.4, Y and Z are described herein. Additionally, the present application describes pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents. Finally, the present application describes methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. ##STR00001##
Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein ##STR00001##
Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment diseases, conditions and/or disorders herein. ##STR00001##
Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein ##STR00001##
Compounds of Formula (I) or (II) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein ##STR00001##
